Log In
Print
BCIQ
Print
Print this Print this
 

HTI-501

  Manage Alerts
Collapse Summary General Information
Company Halozyme Therapeutics Inc.
DescriptionRecombinant human lysosomal proteinase (cathepsin-L)
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase II
Standard IndicationScars / wrinkles
Indication DetailsTreat edematous fibrosclerotic panniculopathy (cellulite); Treat scars/wrinkles
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today